logo
Plus   Neg
Share
Email

Ebix Buys London-based TriSystems - Quick Facts

Ebix Inc. (EBIX) has acquired London-based TriSystems Ltd., an online insurance trading hub facilitating commercial insurance and reinsurance transactions between London intermediaries and insurance companies. The TriSystems products and Services would now become a part of the EbixExchange Division of Ebix Europe.

Further, Ebix expects the merger to be immediately accretive to its earnings per share. The company said the transaction was funded completely in cash, and no Ebix shares were issued and no investment bankers were involved.

The TriSystems On-Demand SaaS platform communicates electronic endorsements and placements with underwriters using ACORD messaging over the Lloyd's Exchange together with Accounting and Settlement or A&S and Electronic Claims File or ECF via. the Insurance Market Repository.

TriSystems Business Development Director, Jeff Ward, said, "Ebix's expertise in the insurance industry coupled with its commitment to open architecture and standards will help us provide an even higher level of quality of services to our customer base. It expands our international reach and also offers us access to Ebix's insurance focused staff of approximately 2000 employees."

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT